The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Open accessAbstract
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent therapies targeting Aβ clearance using anti-Aβ monoclonal antibodies (mabs) during the early stages of AD provide minimal cognitive benefit”
From Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration (2024) · cites this paper as Shi et al. 2022
In the citing paper
“Studies have shown that Aβ buildup can start 15–20 years before clinical symptoms appear, indicating that therapy effectiveness may depend on early intervention [88,89].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 42
RetractedClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Flagged first, then by citations
Research works printed but not linked: 3
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE).
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE).
- Swanson, 2018, Clinical and biomarker updates from BAN2401 Study 201 in early AD, Proceedings of Clinical Trials on Alzheimer’s Disease Conference
Cited by
Sorted by citations
Items 101–200 of 277
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 14
Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 14
Alhodieb, F. S., Rahman, M. A., Barkat, M. A., Alanezi, A. A., Barkat, H. A., Hadi, H. A., Harwansh, R. K., & Mittal, V. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0108 · Cited by 13
Liu, S., Min, Z., Liu, Y., Yang, X., Yan, H., Xu, H. E., Wu, Y., & Xu, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1656906 · Cited by 12
Hao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13
Raghav, D., Shukla, S., & Jadiya, P. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167169 · Cited by 12
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 14
Ashmawy, R. E., Okesanya, O. J., Ukoaka, B. M., Daniel, F. M., Ezedigwe, S. G., Agboola, A. O., Ahmed, M. M., Ogaya, J. B., Amisu, B. O., Adigun, O. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331640 · Cited by 13
Cell-type-specific dysregulation of mitochondrial calcium signaling in Alzheimer’s disease
Shukla, S., Kadam, A. A., Goyani, S., Jaiswal, N., Samantaray, K., Raghav, D., Kashyap, S., Tomar, D., & Jadiya, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02460-0 · Cited by 11
Ferroptosis and Alzheimer’s disease: a new insight into neurodegeneration
Quan, Y., Liu, H., Zhang, M., Li, M., He, B., Wang, K., Huang, X., Zhou, S., Han, Z., & Fan, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1701767 · Cited by 11
Verma, H., Kaur, S., Kaur, S., Gangwar, P., Dhiman, M., & Mantha, A. K. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04053-3 · Cited by 11
Stanciu, G. D., Ababei, D. C., Solcan, C., Urîtu, C. M., Crăciun, V. C., Pricope, C. V., Szilagyi, A., & Tamba, B.-I. (2024) · Pharmaceuticals · doi:10.3390/ph17040530 · Cited by 11
Chakraborty, S., Vishwas, S., Harish, V., Gupta, G., Paudel, K. R., Dhanasekaran, M., Goh, B. H., Zacconi, F. C. M., Pinto, T. D. J. A., Kumbhar, P., et al. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2414768 · Cited by 11
Walker, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157328 · Cited by 11
Shahlaei, M., Afkhami, H., Ahmadieh-Yazdi, A., Mirmazloumi, S. H., Sahraei, S. S., Akbari, M., Yang, P., Manoochehri, H., Tanzadehpanah, H., Mahaki, H., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118548 · Cited by 11
Appleman, M., Thomas, J. L., Weiss, A. R., Nilaver, B. I., Cervera‐Juanes, R. P., Kohama, S. G., & Urbanski, H. F. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1326747 · Cited by 11
Liang, C., Paclibar, C. G., Gonzaga, N. L., Sison, S. A., Bath, H. S., Biju, A. P., & Mukherjee, J. (2024) · Neurology International · doi:10.3390/neurolint16020031 · Cited by 11
Yoon, L., Botham, R. C., Verhelle, A., Wu, Y., Cole, C. M., Tan, E. P., Massey, L. A., Sanz-Martinez, P., Chou, C., Xu, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.509997 · Cited by 11
Menuawy, A. E., Brüning, T., Eiriz, I., Hähnel, U., Marthe, F., Möhle, L., Górska, A. M., Santos‐García, I., Wangensteen, H., Wu, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021301 · Cited by 11
Clinical importance in Alzheimer’s disease: effects of anchor agreement and disease severity
Stojanovic, M., Mikula, C. M., John, S. E., & Kiselica, A. M. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02643-0 · Cited by 10
Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research
Shoemaker, R. L., Larsen, R. J., & Larsen, P. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1426656 · Cited by 10
Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease
Campagna, J. J., Jagodzinska, B. M., Wi, D., Zhu, C., Lee, J. L., Cohn, W., Jun, M., Elias, C. J., Padder, S., Descamps, O., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00610 · Cited by 10
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 11
Li, Z., Zhu, G., Liu, X., Gao, T., Fang, F., Dou, X., Li, Y., Zheng, R., Jin, H., Zhang, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115167 · Cited by 10
Berntsson, E., Vosough, F., Noormägi, A., Padari, K., Asplund, F., Gielnik, M. B., Paul, S., Jarvet, J., Tõugu, V., Roos, P. M., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00130 · Cited by 11
Validation of 3‐ and 5‐point severity scales to assess ARIA‐E
Bracoud, L., Klein, G., Lyons, M., Scelsi, M. A., Wojtowicz, J., Bullain, S., Purcell, D. D., Fiebach, J. B., Barakos, J. A., & Suhy, J. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12503 · Cited by 10
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s
Song, T., Wang, Y., Silverglate, B., & Grossberg, G. T. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2357637 · Cited by 13
Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1
Boldin, R., Zychar, B. C., Gonçalves, L. R. C., & Sciani, J. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1184006 · Cited by 9
Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease
Elghanam, Y., Purja, S., & Kim, E. Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240008 · Cited by 9
Lakela, A. L., Berntsson, E., Vosough, F., Jarvet, J., Paul, S., Barth, A., Gräslund, A., Roos, P. M., & Wärmländer, S. K. T. S. (2025) · Scientific Reports · doi:10.1038/s41598-024-59826-6 · Cited by 10
Myelin organoids for the study of Alzheimer's disease
Cerneckis, J., & Shi, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1283742 · Cited by 9
The aged female rhesus macaque as a translational model for human menopause and hormone therapy
Kohama, S. G., & Urbanski, H. F. (2024) · Hormones and Behavior · doi:10.1016/j.yhbeh.2024.105658 · Cited by 8
Bioinformatic prediction of the molecular links between Alzheimer’s disease and diabetes mellitus
Castillo-Velázquez, R., Martínez-Morales, F., Castañeda‐Delgado, J. E., García-Hernández, M. H., Herrera-Mayorga, V., Sánchez, F. A. P., Rivera, G., Rivas-Santiago, B. T., & Lara-Ramirez, E. E. (2023) · PeerJ · doi:10.7717/peerj.14738 · Cited by 8
Mechanistic insights into the inhibition of amyloid-β aggregation by chitosan
Gotla, S., & Matysiak, S. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp00162h · Cited by 8
Bian, Z.-Y., Li, P., Feng, X.-Y., Zhou, Y., Cheng, F.-Y., Dong, W.-X., Xiang, P., & Tang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116794 · Cited by 8
A Potent Sybody Selectively Inhibits α-Synuclein Amyloid Formation by Binding to the P1 Region
Gialama, D., Vadukul, D. M., Thrush, R. J., Radford, S. E., & Aprile, F. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02408 · Cited by 7
Akkol, E. K., Karatoprak, G. Ş., Dumlupınar, B., Açıkara, Ö. B., Arıcı, R., Yücel, Ç., Aynal, L. C., & Sobarzo‐Sánchez, E. (2025) · Molecules · doi:10.3390/molecules30091982 · Cited by 8
Sadruddin, Z., Harris, K., Bilsborough, E., Sciba, L., Vargas, A. F., Shyer, M. N., Hinojosa, M., Colby, J., Chung, K., Farrell, C. M., et al. (2025) · Geriatric Nursing · doi:10.1016/j.gerinurse.2025.05.010 · Cited by 7
The pulvinar nucleus and its role in cognitive functions
Cortes, N., Mandel, C., Ikan, L., & Casanova, C. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111672 · Cited by 7
Pediaditakis, I., Tsakali, S., Lemieux, M. R., Brennan, M., Robinson, W. H., Papapetropoulos, S., & Papapetropoulos, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100118 · Cited by 8
Elucidating the molecular targets in Alzheimer's disease: Advances and therapeutic implications
Soni, U., & Pujari, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111660 · Cited by 7
Wu, L., Tan, S., Yan, Y., Zhu, L., Wu, Z., Liu, Z., Cheng, Q., Qu, Q., Li, X., Zhang, Q., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153460 · Cited by 7
Schrader, J. M., Majchrzak, M., Xu, F., Lee, H., Agostinucci, K. J., Davis, J., Benveniste, H., & Nostrand, W. E. V. (2024) · Neuroscience Insights · doi:10.1177/26331055241288172 · Cited by 7
Exploring non-canonical targets in Alzheimer’s disease: a departure from the norm
Jain, S., & Chauhan, N. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00908-7 · Cited by 7
Conformational inhibitors of protein aggregation
Fernández‐Ramírez, M. D. C., Afrin, S., & Saelices, L. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102700 · Cited by 6
Patwekar, M., Patwekar, F., Khan, S. M., Sharma, R., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266295495240415114919 · Cited by 8
Rongala, G., Rongala, D. S., & Rongala, A. N. (2025) · Journal of Pharmaceutical and BioTech Industry · doi:10.3390/jpbi2040019 · Cited by 6
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease Patients
McMillan, I. O., Gearing, M., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073964 · Cited by 7
Si, Y., Guo, F., Luo, Y., Zhang, X., Wang, C.-Y., Liu, Y., & Zhang, H. (2024) · Molecules · doi:10.3390/molecules29091907 · Cited by 6
Kim, H., Kulshreshtha, A., Alonso, Á., Goldstein, F. C., Johnson, E. C. B., Gold, M. E., Quyyumi, A. A., & Lah, J. J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251331235 · Cited by 6
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Muronets, V. I., Kudryavtseva, S. S., Kurochkina, L. P., Leisi, E. V., Stroylova, Y. Y., & Schmalhausen, E. V. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604003 · Cited by 5
Bhosale, S. S., Sivakkumar, S., Jamadagni, S. B., & Arulmozhi, S. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00086 · Cited by 5
Esteban-Martos, Á., Brokate-Llanos, A. M., Real, L. M., Melgar‐Locatelli, S., de Rojas, I., Castro‐Zavala, A., Bravo, M. J., Mañas‐Padilla, M. C., García‐González, P., Ruiz‐Galdón, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512079 · Cited by 5
Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia
Choi, S. A., Jee, H. J., Bormate, K. J., Kim, Y., & Jung, Y.-S. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.115 · Cited by 5
Eşmekaya, M. A., & Ertekin, B. (2024) · General Physiology and Biophysics · doi:10.4149/gpb_2024025 · Cited by 6
Mostafa, A., Tiu, S., Khan, F. A., & Baig, N. A. (2025) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_547_24 · Cited by 5
Oba, R., Ujike, N., Ono, Y., Okano, T., & Murakami, T. (2023) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/10406387231204876 · Cited by 5
Role of Amyloid Beta in Neurodegeneration and Therapeutic Strategies for Neuroprotection
Ghosh, P., Narang, K., & Iyer, P. K. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3662-6_25 · Cited by 5
Resistance and Resilience to Alzheimer's DiseasePreprint
Latimer, C. S., Prater, K. E., Postupna, N. O., & Keene, C. D. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041201 · Cited by 8
Role of GABAB receptors in cognition and EEG activity in aged APP and PS1 transgenic mice
Yuan, D., Zhou, Z., Song, M., Zhang, Y., Zhang, Y., Ren, P., Chen, Z., & Fu, Y. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105718 · Cited by 4
Zhang, B., Zhang, D., Chen, K., & Wu, T. (2025) · APOPTOSIS · doi:10.1007/s10495-024-02073-x · Cited by 4
Kim, H. Y., Lee, J., Qian, A., Ji, Y., Zhang, R., Hu, Q., Williams, C. K., Chuang, H., Smalley, M. D., Xu, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202415289 · Cited by 4
Gupta, A., Ghosh, A., Sharma, N., & Gorain, B. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05003-3 · Cited by 4
Dual Aβ/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy
León‐Arcia, K., Pérez-Leal, G., Quintero-Álvarez, H., Zamora-Loyarte, D. I., López-Armenteros, M., Sánchez-Quesada, A. D. L. C., & Vázquez‐Mojena, Y. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127414 · Cited by 4
Shen, K., Liao, M., Nilebäck, E., Hu, X., Gutfreund, P., Petkov, J. T., Olesen, K., & Lu, J. R. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139010 · Cited by 4
Tseng, T., Liaw, C., Shiao, Y., Huang, Y.-I., Cheng, Y.-H., Chen, W.-C., & Tsai, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1673532 · Cited by 4
Shao, S., Hao, L., Zu, R., Chen, Y., Peng, Z., Peng, Q., Ma, H., & Sun, Y. (2025) · Phytotherapy Research · doi:10.1002/ptr.70131 · Cited by 4
A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease
Sharma, C., & Mazumder, A. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249263300231116062740 · Cited by 4
Bulgart, H. R., Perez, M. A. L., Tucker, A., Giarrano, G. N., Banford, K. K., Miller, O., Bonser, S. W. G., Wold, L. E., Scharre, D. W., & Weisleder, N. L. (2024) · The FASEB Journal · doi:10.1096/fj.202401731rr · Cited by 4
Label-free ADAM10 capacitive assay for the early diagnosis of Alzheimer’s disease
Garrote, B. L., Lopes, L. C., Cominetti, M. R., Faria, R. C., & Bueno, P. R. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137208 · Cited by 4
Accelerated neuronal aging in vitro ∼melting watch ∼
Inagaki, E., Yoshimatsu, S., & Okano, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.868770 · Cited by 4
Wang, M., Yang, X., Gao, Y., & Han, W. (2023) · Foods · doi:10.3390/foods12030635 · Cited by 4
Interactions of Cellular Energetic Gene Clusters in the Alzheimer’s Mouse Brain
Raju, R. P., Cai, L., Tyagi, A., & Pugazhenthi, S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03551-0 · Cited by 3
Soler-Sáez, I., Karz, A., Hidalgo, M. R., Gómez-Cabañes, B., López‐Cerdán, A., Català-Senent, J. F., Prutisto-Chang, K., Eskow, N. M., Izar, B., Redmer, T., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.09.005 · Cited by 3
Davidson, M., Stanciu, G. D., Rabinowitz, J., Untu, I., Dobrin, R., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2480566 · Cited by 3
Bhansali, P. R., Sonkusare, S. M., Savale, S. S., Wijayasinghe, Y. S., Liao, Y., Sloan, D. C., Chaturbhuj, G. U., & Muntean, B. S. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1642190 · Cited by 3
NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study
Pérez, S. S., Amable, N. U., González, C. E. V., Lorenzo-Luaces, P., Sánchez, L., Crombet, T., León, K., Obaya, T. R., & Ruíz, L. P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251386885 · Cited by 3
Combining AI design and molecular dynamics to disrupt amyloid aggregation in Alzheimer’s disease
Esmaeilzadeh, A., Irani, M. A., Javanmard, A., & Khezri, M. G. (2026) · Discover Applied Sciences · doi:10.1007/s42452-026-08245-5 · Cited by 3
Recent advances towards BACE1 drug discovery and therapeutics design
Imran, S., Patel, M., Noroozifar, M., & Kerman, K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01095k · Cited by 4
Diffusion imaging markers of accelerated aging of the lower cingulum in subjective cognitive decline
Flaherty, R., Sui, Y. V., Masurkar, A. V., Betensky, R. A., Rusinek, H., & Lazar, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1360273 · Cited by 3
Pro-cognitive efficacy of Prospekta in a rat model of age-associated cognitive impairment
Kardash, E., Petrova, N., Ganina, K., Тарасов, С. А., & Epstein, O. I. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00958-4 · Cited by 3
A dementia ellátása a háziorvosi gyakorlatban
Zsuffa, J. A., Kalabay, L., Katz, S., Kamondi, A., Csukly, G., & Horvath, A. A. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32816 · Cited by 3
Combination Drug Therapy for the Management of Alzheimer’s Disease
Dudchenko, N. G., & Mkhitaryan, E. A. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-2-2024-140-144 · Cited by 2
Mizuno, A., Nakayoshi, T., Inaoka, K., Shingaki, A., Kurimoto, E., Kato, K., & Oda, A. (2025) · ChemBioChem · doi:10.1002/cbic.202500171 · Cited by 2
Saiz-Vázquez, O., Landa, S. U., & Puente-Martínez, A. (2025) · Kidney & Blood Pressure Research · doi:10.1159/000546395 · Cited by 3
Down syndrome and a presenilin 2 variant: dual genetic risk of Alzheimer’s disease
Ogg, J. D., Postupna, N. O., Gibbons, L. E., Ariza, J., Xiao, M., Fonseca, L. M., Jayadev, S., Keene, C. D., Bird, T. D., & Latimer, C. S. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02931-1 · Cited by 2
Kinetic Model with Feedback Cycle for Age-Dependent Amyloid Beta Accumulation in Mice
Tyng, V., & Kellman, M. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188803 · Cited by 2
Nath, R., Bhattacharjee, S., Ashique, S., Panda, S., Maiti, N. J., Akhtar, M. J., Debnath, I., Hussain, M. S., Debnath, B., Attar, J. R., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144837 · Cited by 2
Jiang, A., Shi, D., Que, X., Lin, Z., Chen, Y., Huang, Y., Liu, C., Wen, Y., Zhang, S., & Huang, W. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1585761 · Cited by 2
Epigenetic regulons in Alzheimer's disease
Raval, M., Mishra, S., & Tiwari, A. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.01.012 · Cited by 2
An emerging spectrum of therapeutic targets for Alzheimer's disease
Goetzl, E. J. (2023) · The FASEB Journal · doi:10.1096/fj.202301461r · Cited by 2
Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice
Ma, H., Zheng, J., Qiu, Y.-H., Su, S., Lu, F.-M., Wu, G., Zhang, S., & Cai, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119016 · Cited by 2
Lin, Y., Lin, L., Kao, C.-H., Chen, I.-J., Cheng, C., Tsai, C.-L., Lee, J., Sung, Y., Chou, C.-H., Yen, S.-Y., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226855 · Cited by 2
The Proof-of-Concept of MBA121, a Tacrine–Ferulic Acid Hybrid, for Alzheimer’s Disease Therapy
Rodríguez-Ruiz, E. R., Herrero-Labrador, R., Fernández-Fernández, A. P., Serrano, J., Martínez-Montero, J. A., González‐Nieto, D., Vaish, M., Benchekroun, M., Ismaïli, L., Marco‐Contelles, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512254 · Cited by 2
Lee, J.-W., Kim, M., Kim, H., Kim, S., Um, Y. H., Wang, S., Lim, H. K., Lee, C. U., & Kang, D. W. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1410185 · Cited by 2
Wu, S., Qi, Y., Jiang, C., & Zheng, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2448205 · Cited by 2
Liu, M., Zhu, L., Li, F., Shi, X., Shen, Y.-F., & Liu, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.06.579113 · Cited by 2
Metadata
- Authors
- Shi, M., Chu, F., Zhu, F., & Zhu, J.
- Affiliations
- First Hospital of Jilin University (CN)
- Shenzhen University (CN)
- Karolinska University Hospital (SE)
- Corresponding author
- Zhu, Feiqi
- Zhu, Jie
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-04-12
- Volume
- 14
- Pages
- 870517-870517
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC9039457
- OpenAlex
- W4223533048
- Cited by
- 275
- References
- 97
- Citations by year
- 2026: 28 · 2025: 66 · 2024: 104 · 2023: 68 · 2022: 8
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- People's Government of Jilin Province
- Jilin University
- Sanming Project of Medicine in Shenzhen (SZSM201801014)
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid beta monoclonal antibody, aducanumab, lecanemab, amyloid plaques, disease-modifying therapy, immunotherapy, clinical trial results, adverse effects, amyloid-beta clearance, tau hyperphosphorylation, neurofibrillary tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
